FPC
NERV icon

Falcon Point Capital’s Minerva Neurosciences NERV Stock Holding History

Falcon Point Capital’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,492
Closed -$351K – 108
2018
Q3 		$351K Buy
3,492
+776
+29% +$58.3K 0.08% 84
2018
Q2 		$179K Buy
+2,716
New +$165K 0.04% 114

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return

Falcon Point Capital's NERV Position: Q4 2018 in Review

Falcon Point Capital sold out of Minerva Neurosciences (NERV) in Q4 2018, closing a stake of 3,492 shares — an estimated $351K sold.

Falcon Point Capital first reported a position in NERV in Q2 2018 and held it in 2 quarters. The position peaked at $351K in Q3 2018. 84 funds tracked by Wall St. Rank hold NERV as of Q4 2018.

  • Falcon Point Capital reported no remaining Minerva Neurosciences position as of Q4 2018 after selling out during the quarter.
  • Falcon Point Capital sold 3,492 Minerva Neurosciences shares in Q4 2018, an estimated $351K.
  • Falcon Point Capital first reported a position in Minerva Neurosciences in Q2 2018 and held it in 2 quarters.
  • Falcon Point Capital's Minerva Neurosciences position peaked at $351K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2018.

Based on Falcon Point Capital's 13F filing for Q4 2018, filed 31 Jan 2019.